SCHEMBL7573159

SCHEMBL7573159

O=C(O)c1cccc(F)c1Nc1c(Nc2cccc(Br)c2)c(=O)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 4/20 0.47
EGFR P00533 1/20 0.44
ERBB2 P04626 1/20 0.44
MPO P05164 1/20 0.43
EPM2A O95278 1/20 0.41
PTPN1 P18031 1/20 0.41
PTPN6 P29350 1/20 0.41
PTPN9 P43378 1/20 0.41
DUSP3 P51452 1/20 0.41
PTPN11 Q06124 1/20 0.41
RAPGEF4 Q8WZA2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HTT P42858 1/20 0.40
GRIK1 P39086 2/20 0.40
P2RX1 P51575 1/20 0.40
GRIK2 Q13002 1/20 0.40
AURKA O14965 2/20 0.39
ALB P02768 1/20 0.39
MAOB P27338 1/20 0.39
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7577106 0.87 CXCR2 (0.52) CXCR2EGFRERBB2MPOEPM2A
SCHEMBL7571639 0.87 CXCR2 (0.49) CXCR2EGFRERBB2MPOEPM2A
SCHEMBL7572551 0.82 CXCR2 (0.63) CXCR2MPOGRIK1GRIK2TAS2R14
SCHEMBL3636604 0.79 KMT2A (0.54) CXCR2ALDH1A1AURKAALBKMT2A
SCHEMBL7586739 0.74 CXCR2 (0.47) CXCR2GRIK1KMT2ATAS2R14MEN1
SCHEMBL384593 0.72 FABP4 (0.65) MPOALDH1A1HTTGRIK1P2RX1
SCHEMBL7595003 0.72 CXCR2 (0.52) CXCR2MPOALDH1A1GRIK1KMT2A
SCHEMBL28289321 0.68 KDM4E (0.64) CXCR2MPOHTTGRIK1ALB
SCHEMBL17060022 0.68 CYP3A4 (0.60) CXCR2EGFRERBB2RAPGEF4ALDH1A1
SCHEMBL30715849 0.67 MPO (0.49) MPORAPGEF4HTTGRIK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1117633-B1 DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH AS (DK) 2002-09-18 EP disclosed
US-6413996-B2 CHLORIDE CHANNEL BLOCKERS; FOR TREATMENT OF SICKLE CELL ANAEMIA, BRAIN OEDEMA FOLLOWING ISCHAEMIA OR TUMOURS, DIARRHOEA, HYPERTENSION (DIURETIC), OSTEOPOROSIS, BONE METASTASIZING CANCERS NEUROSEARCH A/S (DK) 2002-07-02 US disclosed
US-20010056092-A1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use ANIONA APS (DK) 2001-12-27 US disclosed
EP-1117633-A1 DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2001-07-25 EP disclosed
WO-2000020378-A1 DIAMINOCYCLOBUTENE-3,4-DIONE DERIVATIVES, THEIR PREPARATION AND USE NEUROSEARCH A/S (DK) 2000-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010056092-A1 Diaminocyclobutene-3,4-dione derivatives, their preparation and use HCN4, CLIC1, KCNB1 CXCR2 415/4885EGFR 2204/4885ERBB2 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.